SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?


To: Anthony Wong who wrote (427)11/24/1998 8:49:00 PM
From: Anthony Wong  Respond to of 642
 
Update on Actos:

Another potential threat to Warner-Lambert's (WLA) second largest product, Rezulin, is Eli Lilly's (LLY) & Takada's Actos (an insulin sensitizer). Takada had a presentation in Japan regarding this drug and stated that it shows no liver toxicity (unlike Rezulin). This product is expected to be on the market in early 2000.

From labpuppy.com
labpuppy.com